Adding the CDK4/6 inhibitor abemaciclib to endocrine therapy significantly improves overall survival in node-positive, high-risk early breast cancer, in the extended follow-up of a landmark trial.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/abemaciclib-ups-overall-survival-high-risk-breast-cancer-2025a1000san?src=rss
Author :
Publish date : 2025-10-18 14:25:00
Copyright for syndicated content belongs to the linked Source.